Margherita Rimini
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 115 publications
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.
Journal: ESMO gastrointestinal oncology
Published: May 22, 2026
Reply to: "Establish a streamlined molecular profiling workflow for the clinical management of advanced cholangiocarcinoma".
Journal: Journal of hepatology
Published: May 05, 2026
The evolving role of futibatinib for advanced cholangiocarcinoma.
Journal: Expert review of gastroenterology & hepatology
Published: March 23, 2026
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab.
Journal: International journal of cancer
Published: March 23, 2026
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.
Journal: International journal of cancer
Published: February 15, 2026
Proof-of-principle 4-marker spatial profiling reveals distinct, location-independent immune clusters in biliary tract cancers.
Journal: Pathology oncology research : POR
Published: February 13, 2026
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 07, 2026
Comprehensive genetic analysis in biliary tract cancer: a prospective single-center experience.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group).
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: January 24, 2026
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: November 23, 2025
Last Updated: 09/26/2026